GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry